7/6/2009

Johnson & Johnson announced that it will pay $1.5 billion to acquire an 18.4% stake in Elan and gain rights to the biotech firm's drug portfolio for Alzheimer's disease. J&J will pay for continuing the development of bapineuzumab, one of Elan's Alzheimer's drug candidates in late-stage studies.

Related Summaries